CLL
4
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
BeOne MedicinesCA - San Carlos
2 programs2
BGB-16673Phase 31 trial
SonrotoclaxPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BeOne MedicinesBGB-16673
BeOne MedicinesSonrotoclax
Kyowa Hakko KirinZandelisib
TG TherapeuticsTG-1801
Clinical Trials (4)
Total enrollment: 923 patients across 4 trials
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Start: Apr 2025Est. completion: Feb 2030250 patients
Phase 3Recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Start: Nov 2023Est. completion: Dec 2032652 patients
Phase 3Active Not Recruiting
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Start: Nov 2022Est. completion: Mar 20230
Phase 2Withdrawn
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Start: Apr 2021Est. completion: Jun 202421 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 923 patients
3 companies competing in this space